Indian shares set to open marginally higher; Tech Mahindra in focus
BENGALURU, July 26 (Reuters) -Indian shares are likely to open marginally higher on Friday, after logging losses in the previous five sessions, with analysts expecting earnings-led stock-specific reactions to guide the intraday trajectory.
The GIFT Nifty GIFc1 was at 24,486 points, as of 8:16 a.m. IST, suggesting that the Nifty 50 index .NSEI will open slightly above its Thursday's close of 24,406.1.
Weaker-than-expected results from Reliance Industries RELI.NS, Wipro WIPR.NS, Bajaj Finance BJFN.NS, Axis Bank AXBK.NS and Nestle NEST.NS have weighed on markets through the course of the week, as did the union budget on Tuesday, in which tax hikes on capital gains in equity investments and derivatives trading were announced.
"Overall, we expect the market to continue seeing incremental moves on Friday with stock-specific action guiding the trajectory given the earnings season is in full swing," said Siddhartha Khemka, head of retail research, Motilal Oswal Financial Services.
Tech Mahindra TEML.NS will be in focus after the information technology firm beat its estimates for June-quarter revenue. The company said it expects a "better fiscal year 2025, compared with the previous one."
Asian markets were trading lower on the day, while most Wall Street equities logged losses in a choppy overnight session. MKTS/GLOB
Investors await the U.S. personal consumption expenditures (PCE) data - the Federal Reserve's preferred gauge of inflation - due after the closing bell to confirm bets of an early start of rate cuts.
Data showed on Thursday that the U.S. economy grew faster than expected in second quarter, keeping intact the expectations that the Fed will begin cutting interest rates in September.
Foreign institutional investors (FIIs) remained sellers for the third straight session on Thursday, with the outflows since union budget rising to about $1.3 billion.
STOCKS TO WATCH
** AU Small Finance Bank: Company reports a rise in net profit in June quarter, and also announces plans to apply to the Reserve Bank of India for a Universal Bank license.
** Mankind Pharma MNKI.NS: Drugmaker says it will acquire Bharat Serums and Vaccines from U.S.-based private equity firm Advent International in a deal valued at about 136.30 billion rupees ($1.63 billion).
** Cyient CYIE.NS: Company posts drop in June-quarter profit on delays in project execution.
** United Spirits UNSP.NS: Company's chief execution has been summoned by Delhi city police in liquor payments case, Reuters reported.
($1 = 83.7330 Indian rupees)
Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sherry Jacob-Phillips
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
